PL372303A1 - Nowe krystaliczne postaci soli hemi-wapniowej atorwastatyny i sposoby ich wytwarzania oraz nowe sposoby wytwarzania postaci I, VIII i IX soli hemi-wapniowej atorwastatyny - Google Patents

Nowe krystaliczne postaci soli hemi-wapniowej atorwastatyny i sposoby ich wytwarzania oraz nowe sposoby wytwarzania postaci I, VIII i IX soli hemi-wapniowej atorwastatyny

Info

Publication number
PL372303A1
PL372303A1 PL03372303A PL37230303A PL372303A1 PL 372303 A1 PL372303 A1 PL 372303A1 PL 03372303 A PL03372303 A PL 03372303A PL 37230303 A PL37230303 A PL 37230303A PL 372303 A1 PL372303 A1 PL 372303A1
Authority
PL
Poland
Prior art keywords
calcium
processes
atorvastatin hemi
novel
forms
Prior art date
Application number
PL03372303A
Other languages
English (en)
Inventor
Limor Tessler
Judith Aronhime
Revital Lifshitz-Liron
Dalia Maidan-Hanoch
Nir Hasson
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of PL372303A1 publication Critical patent/PL372303A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
PL03372303A 2002-02-15 2003-02-19 Nowe krystaliczne postaci soli hemi-wapniowej atorwastatyny i sposoby ich wytwarzania oraz nowe sposoby wytwarzania postaci I, VIII i IX soli hemi-wapniowej atorwastatyny PL372303A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35718102P 2002-02-15 2002-02-15
US42532502P 2002-11-12 2002-11-12

Publications (1)

Publication Number Publication Date
PL372303A1 true PL372303A1 (pl) 2005-07-11

Family

ID=27760457

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372303A PL372303A1 (pl) 2002-02-15 2003-02-19 Nowe krystaliczne postaci soli hemi-wapniowej atorwastatyny i sposoby ich wytwarzania oraz nowe sposoby wytwarzania postaci I, VIII i IX soli hemi-wapniowej atorwastatyny

Country Status (14)

Country Link
EP (1) EP1480950A4 (pl)
JP (2) JP2005519076A (pl)
KR (1) KR100724515B1 (pl)
CN (1) CN100406436C (pl)
AU (1) AU2003217653A1 (pl)
CA (1) CA2475864A1 (pl)
DE (1) DE03713610T1 (pl)
ES (1) ES2241507T1 (pl)
HR (1) HRP20040768A2 (pl)
IS (1) IS7402A (pl)
MX (1) MXPA04007939A (pl)
NO (1) NO20043842L (pl)
PL (1) PL372303A1 (pl)
WO (1) WO2003070702A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
KR20090045420A (ko) 2002-02-19 2009-05-07 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미-칼슘 용매화합물의 탈용매화
WO2004050618A2 (en) * 2002-11-28 2004-06-17 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
EP1771412A2 (en) * 2004-07-20 2007-04-11 Warner-Lambert Company LLC Crystalline forms of [r-(r*)]-2-(4-fluorophenyl)-bet a,gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid calcium salt (2:1)
DE202005020766U1 (de) * 2004-07-22 2006-10-05 Teva Pharmaceutical Industries Ltd. Neue Kristallformen von Atorvastatin-Hemi-Calcium
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
CZ2007772A3 (cs) * 2005-04-08 2008-02-27 EGIS GYOGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság Nová krystalická polymorfní forma hemivápenaté soli atorvastatinu
US8084488B2 (en) 2005-11-21 2011-12-27 Pfizer Inc. Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
BRPI0610344A2 (pt) 2005-12-13 2016-11-29 Teva Pharma forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
RU2421445C1 (ru) 2007-03-02 2011-06-20 Донг-А Фарм. Ко., Лтд. Новые кристаллические формы производных пирролилгептановой кислоты
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
KR101324862B1 (ko) * 2011-07-12 2013-11-01 (주)에이에스텍 클로피도그렐 황산수소염의 구형 입자, 이를 포함하는 약학적 조성물 및 이의 제조방법
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
CN105055357A (zh) * 2015-09-25 2015-11-18 青岛华之草医药科技有限公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
KR101723783B1 (ko) * 2017-02-24 2017-04-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
DE69616808T2 (de) * 1995-07-17 2002-05-29 Warner Lambert Co Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin)
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
IL149681A0 (en) * 1999-11-17 2002-11-10 Teva Pharma Polymorphic form of atorvstatin calcium
HUP0203708A3 (en) * 1999-12-17 2003-11-28 Warner Lambert Res & Dev Ie A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt
CA2391357C (en) * 1999-12-17 2009-01-06 Warner Lambert Research And Development Ireland Limited A process for producing crystalline atorvastatin calcium
MXPA03003900A (es) * 2000-11-03 2005-02-17 Teva Pharma Forma vii de hemicalcio de atorvastatina.
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (en) * 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
PL367943A1 (pl) * 2001-06-29 2005-03-07 Warner-Lambert Company Llc Krystaliczne formy soli wapniowej kwasu [R-(R, R)]-2-(4-fluorofenylo)-Beta, Delta-dihydroksy-5-(1-metyloetylo)-3-fenylo-4-[(fenyloamino) karbonylo]-1H pirolo-1-heptanowego (2:1) (atorvastatyny)
CA2454500C (en) * 2001-07-30 2009-11-10 Dr. Reddy's Laboratories Ltd. Crystalline forms vi and vii of atorvastatin calcium
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
JP2006503024A (ja) * 2002-09-03 2006-01-26 モレペン、ラボラトリーズ、リミテッド Ｖｉ型アトルバスタチンカルシウムまたはその水和物
WO2004050618A2 (en) * 2002-11-28 2004-06-17 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt

Also Published As

Publication number Publication date
KR100724515B1 (ko) 2007-06-04
NO20043842L (no) 2004-09-14
CN100406436C (zh) 2008-07-30
HRP20040768A2 (en) 2005-06-30
IS7402A (is) 2004-08-13
EP1480950A1 (en) 2004-12-01
DE03713610T1 (de) 2005-10-20
CA2475864A1 (en) 2003-08-28
WO2003070702A1 (en) 2003-08-28
AU2003217653A1 (en) 2003-09-09
KR20040081202A (ko) 2004-09-20
JP2009235083A (ja) 2009-10-15
JP2005519076A (ja) 2005-06-30
CN1646490A (zh) 2005-07-27
EP1480950A4 (en) 2005-05-18
MXPA04007939A (es) 2004-11-26
ES2241507T1 (es) 2005-11-01

Similar Documents

Publication Publication Date Title
EP1480950A4 (en) NOVEL HEMI-CALCIUM CRYSTALLINE FORMS OF ATORVASTATIN AND METHODS FOR THEIR PREPARATION, AS WELL AS NEW METHODS FOR THE PREPARATION OF FORORVASTATIN HEMI-CALCIUM FORMS I, VIII AND IX
HUP0600538A2 (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
PL377555A1 (pl) Nowe krystaliczne postaci soli hemi-wapniowej atorwastatyny i sposoby ich wytwarzania oraz nowe sposoby wytwarzania innych postaci
HRP20150163T1 (en) Process for the preparation of n-substituted 2-cyanopyrrolidines
HK1084114A1 (en) Compounds for synthesizing intermediate useful in the preparation of atorvastatin
WO2003070725A3 (en) Process for preparing indolinone derivatives
AU2003245572A1 (en) Preparation of chiral amino-nitriles
AU2003230457A1 (en) Compression of containers
IL180708A0 (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
IL173012A0 (en) Process and intermediate compounds useful in the preparation of statins, particularly atorvastatin
AU2003297594A1 (en) Crystalline form f of atorvastatin hemi-calcium salt
HK1081950A1 (en) 1-Oxa-dibenzoazolenes as inhibitors of thmour necrosis factor production and intermediates for the preparation thereof
EP1547993A4 (en) PROCESS FOR PREPARING SPIROFLUORENOLS
AU2002367890A1 (en) Process for the preparation of 4-methyl-thiazole-5-carbaldehyde intermediate
AU2003216848A1 (en) Deracemisation of amines
AU2003217438A1 (en) Novel crystalline forms of levetiracetam
AU2002358357A1 (en) Improvements relating to frequency synthesis
PL1685104T3 (pl) Sposoby wytwarzania N-podstawionych ftalimidów
AU2003302645A1 (en) Synthesis of pyrrolidine compound and salt thereof
AU2003262704A1 (en) Synthesis of gatifloxacin
EP1486485A4 (en) NEW 5-HYDROXYCARBAMIMIDOYL-2-HYDROXYBENZENESULFONAMIDE DERIVATIVE CRYSTALS
AU2003235129A1 (en) Process for preparation of 2-aminoketones
AU2003296482A1 (en) Tetracyclines as anti-fungal agents for treatment of ringworm
LT2004018A (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
AU2002249557A1 (en) COMBUSTION PROCESS FOR THE PREPARATION OF LiCoVO4

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)